Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.

Article Details

Citation

Copy to clipboard

Lee YS, Jun HS

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.

Metabolism. 2014 Jan;63(1):9-19. doi: 10.1016/j.metabol.2013.09.010. Epub 2013 Oct 17.

PubMed ID

24140094 [ View in PubMed

]

Abstract

Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L-cells in response to nutrients. GLP-1 lowers blood glucose levels by stimulating insulin secretion from pancreatic beta-cells in a glucose-dependent manner. In addition, GLP-1 slows gastric emptying, suppresses appetite, reduces plasma glucagon, and stimulates glucose disposal, which are beneficial for glucose homeostasis. Therefore, incretin-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase IV, an enzyme which inactivates GLP-1, have been developed for treatment of diabetes. This review outlines our knowledge of the actions of GLP-1 on insulin secretion and biosynthesis, beta-cell proliferation and regeneration, and protection against beta-cell damage, as well as the involvement of recently discovered signaling pathways of GLP-1 action, mainly focusing on pancreatic beta-cells.

DrugBank Data that Cites this Article

Drugs

Semaglutide

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Semaglutide	Glucagon-like peptide 1 receptor	Protein	Humans	Yes	Agonist	Details